Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURETHAL Grasses rush versus conventional induction safety study
2009-015012-18Phase 4Completed
- Sponsor
- HAL Allergy Group
- Start
- Nov 2009
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Purethal in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by HAL Allergy Group. Primary endpoint: Successful reaching of maintenance dose. Started Nov 2009; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2009-015012-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015012-18.